(Circulation. 2000;102:3137.)
© 2000 American Heart Association, Inc.
Special Report |
Trends and Disparities in Coronary Heart Disease, Stroke, and Other Cardiovascular Diseases in the United States
Findings of the National Conference on Cardiovascular Disease Prevention
Correspondence to Lawrence Friedman, MD, National Heart, Lung, and Blood Institute, National Institutes of Health, 31 Center Dr, MSC 2482, Bethesda, MD 20892-2482.
 |
Abstract |
|---|
 Top Abstract IntroductionRecent Trends in CVD...Recent Trends in Levels...Recent Trends in CVD...Strategic Overview of New...Areas Where New or...A More Effective Strategic...DiscussionReferences |
|---|
Abstract—A workshop was held September 27 through 29, 1999, to address issues relating to national trends in mortality and morbidity from cardiovascular diseases; the apparent slowing of declines in mortality from cardiovascular diseases; levels and trends in risk factors for cardiovascular diseases; disparities in cardiovascular diseases by race/ethnicity, socioeconomic status, and geography; trends in cardiovascular disease preventive and treatment services; and strategies for efforts to reduce cardiovascular diseases overall and to reduce disparities among subpopulations. The conference concluded that coronary heart disease mortality is still declining in the United States as a whole, although perhaps at a slower rate than in the 1980s; that stroke mortality rates have declined little, if at all, since 1990; and that there are striking differences in cardiovascular death rates by race/ethnicity, socioeconomic status, and geography. Trends in risk factors are consistent with a slowing of the decline in mortality; there has been little recent progress in risk factors such as smoking, physical inactivity, and hypertension control. There are increasing levels of obesity and type 2 diabetes, with major differences among subpopulations. There is considerable activity in population-wide prevention, primary prevention for higher risk people, and secondary prevention, but wide disparities exist among groups on the basis of socioeconomic status and geography, pointing to major gaps in efforts to use available, proven approaches to control cardiovascular diseases. Recommendations for strategies to attain the year 2010 health objectives were made.
Key Words: cardiovascular diseases • epidemiology • prevention
|
Introduction |
|---|
|
TopAbstractIntroductionRecent Trends in CVD...Recent Trends in Levels...Recent Trends in CVD...Strategic Overview of New...Areas Where New or...A More Effective Strategic...DiscussionReferences |
|---|
The 20th century witnessed dynamic, worldwide changes in cardiovascular disease (CVD) mortality, including death from coronary heart disease (CHD), stroke, and other CVDs. Many Western countries documented a rise in mortality from CVD until the 1960s and 1970s, with substantial declines since those peaks. Other parts of the world have shown different patterns, including high rates of CVD mortality in Eastern Europe that continue to rise and an ominous epidemic of CHD and stroke emerging in developing countries.1 In the United States, recent evidence has suggested that the decline in CHD mortality since the late 1960s has slowed. This may be especially true in specific subgroups (defined by socioeconomic status, race or ethnicity, and region), whose declines have lagged. This has led to relatively higher CVD rates, which constitute a major challenge to reaching the Healthy People 2010 Objectives set for the American people.2 The causes of these disparities in CVD burden are primarily environmental and likely include differences in CVD risk factors, lifestyle, and the availability and use of primary and secondary preventive services.
The National Conference on CVD Prevention was a transagency conference convened at the encouragement of the US Congress3 from September 27 through 29, 1999, in Bethesda, Maryland to assess the magnitude and causes of trends in CHD, stroke, and other CVDs; to examine various explanations for increasing health disparities across socioeconomic status, race/ethnicity, and region; and to explore opportunities to rectify these disparities. The Conference had the following 5 objectives.
1. To examine trends in levels of CVD mortality (and morbidity, if possible) in the US population as a whole and in selected subpopulations
2. To describe trends in levels of CVD risk factors by both behavior (eg, diet, exercise, and tobacco use) and physiology (eg, serum lipids, blood pressure, obesity, and diabetes) in the US population as a whole and in selected subpopulations in parallel to CVD mortality trends as a way to better understand observed disparities in CVD mortality.
3. To estimate trends in levels of cardiovascular health services, including primary prevention, secondary prevention, and rehabilitation, in parallel to CVD mortality trends as a way to understand the influence of disparities in health care and disparities in CVD mortality trends.
4. To identify areas where new or better data are needed to attain the Year 2010 Health Objectives for the Nation so as to target those areas as part of the strategic research agenda for the 21st century.
5. To develop a more effective strategic agenda for CVD prevention programs and policies to reduce disparities among subpopulations in CVD mortality, morbidity, risk factors, and healthcare services as a means to reduce CVD mortality in the US population as a whole and to meet 2010 Health Objectives.
The Conference had roots in 3 previous conferences that endeavored to describe and explain changes in CVD mortality in the last quarter of the 20th century. The first, "The Conference on the Decline in Coronary Heart Disease Mortality,"4 was convened in 1978 and verified the newly described downward trend in CVD mortality but was unable to identify precisely the causes for these declines. The second, "Trends and Determinants of Coronary Heart Disease Mortality: The Influence of Medical Care,"5 was held in 1986 to examine the contributions of preventive and therapeutic patient management; it concluded that some of the decline in CVD mortality could indeed be attributed to preventive and early medical care. The third, "Trends and Determinants of Coronary Artery Disease Mortality: International Comparisons,"6 was convened in 1988 to make international comparisons of CHD mortality, morbidity, risk factors, and medical care and to seek explanations for worldwide variations in CHD incidence, prevalence, mortality, case fatality rates, and trends.
This report summarizes the findings of the 1999 Conference on CVD Prevention. It aims to provide a better picture of the cardiovascular health of the United States and to propose a strategic agenda for research to enhance the understanding of and to improve CVD indicators and to create policies and programs that will more effectively prioritize and implement CVD control efforts over the next decade.
|
Recent Trends in CVD Mortality in the United States |
|---|
|
TopAbstractIntroductionRecent Trends in CVD...Recent Trends in Levels...Recent Trends in CVD...Strategic Overview of New...Areas Where New or...A More Effective Strategic...DiscussionReferences |
|---|
CVD has been recognized as the dominant cause of death in the United States for at least 50 years, with heart disease ranking first and stroke ranking third as specific causes of death. CVD accounts for >900 000 deaths annually in the United States7 ; 12 million Americans have CHD, and another 4 million have had a stroke.8 9 Despite the enormous magnitude of the current CVD burden, the United States has been the beneficiary of substantial declines in both CHD and stroke mortality (Figure 1
).8 9 10 11
CHD mortality declines began in the 1960s. In contrast, stroke rates
have generally declined from about 1920 to 1990, with more pronounced
declines from 1970 to 1990.
|
An impetus for the National Conference on CVD Prevention was
the perception that the declines in CHD and stroke rates since 1990 had
slowed (Table 1). Age-adjusted CHD mortality rates decreased at
>3% per year for the 20-year period between 1970 and 1990. However,
for the 7-year period between 1990 and 1997, CHD mortality declined at
a rate of 2.7%
(Table 1). Perhaps more striking were the findings for
stroke mortality, which had sizable reductions in both the 1970s and
1980s but much more modest reductions since 1990. Others have
documented this flattening of the stroke
trend.12 13 14
These trends have generally been observed for both men and women and in
both middle-aged and older Americans (data not shown).
|
Another important cause of CVD death is congestive heart failure. This disease serves as a fatal sequela of several CVDs, including CHD, hypertension, valvular heart disease, and idiopathic cardiomyopathy. Currently 4.6 million Americans have congestive heart failure, and there are 550 000 new cases annually.8 9 It is the only category of CVD in which prevalence, incidence, and mortality seem to have increased in most years over the past 25 years. With the aging of the population and declines in mortality from other forms of CVD, it is likely that congestive heart failure will continue to increase in public health importance.15
Recent Trends in CVD Mortality by Race and
Ethnicity
CHD and stroke mortality rates differ among the major
ethnic groups in the United States
(Table 2) (National Center for Health Statistics, personal
communication, August
2000).11 Blacks
have the highest rates of CHD, and non-Hispanic whites also
have relatively high CHD mortality. Native Americans, Asians, and
Hispanics have lower rates. CHD mortality rates are especially high in
middle-aged black men relative to other race/sex groups, and stroke
mortality rates are strikingly higher in blacks in general. Native
Americans and Hispanics have the lowest stroke rates.
|
Early in the decline of CHD and stroke, CVD death rates in
all major demographic groups declined in parallel. However, since the
mid-1980s, the documented trends in CHD have diverged across race/sex
subgroups
(Figure 2).10 16 17 18
The rates of CHD mortality have declined more slowly in black men than
in white men. Although white men at one time had higher age-adjusted
(to the year 2000 standard) rates than black men, the rates are now
almost identical. The declines in CHD mortality rates among black women
have also been somewhat slower than among white women; black women have
had higher rates since the mid-1980s
(Figure 2).
|
Recent Trends in CVD Mortality by Socioeconomic
Group
Steep gradients in CVD mortality are observed across
socioeconomic status, as measured by education, income, or
occupation.19 20
Socioeconomic status stratum–specific trends in CVD have been more
difficult to ascertain because of limitations in national data. There
is evidence that the CVD mortality decline began later in women with a
lower socioeconomic status than in those with a higher socioeconomic
status.21 Data from US
metropolitan areas show a graded relationship between income inequality
(a measure of maldistribution of wealth across a population) and heart
disease mortality.22 There
is also strong documentation for trends in total mortality, to which
CVD is a substantial contributor, showing that the gap between lower
and higher socioeconomic status has
widened.23 24
Overall, the available data suggest that the gap in CVD mortality
between the poor and undereducated versus the wealthy and well-educated
has not lessened and may be widening.
Recent Trends in CVD Mortality by
Geography
CVD mortality rates vary markedly by region in the
United States, with age-adjusted CHD rates varying >2-fold between the
states with the highest and lowest rates. However, state-level mapping
of CVD mortality provides only a crude measure of disease distribution;
finer geographic or economic units are needed to refine the patterns.
Maps of CVD based on areas smaller than states have been available
since the 1960s; they describe the decline in CVD as a function of
geography.22 CVD mortality
first began declining in the Northeast United States as early as 1962,
with areas of the South showing no decline until 1970. Relative to the
United States as a whole, many areas of Appalachia experienced low
levels of CVD mortality in the 1950s, whereas by 1968 to 1978, their
rates were among the highest. Similarly, relatively high rates in areas
of the Western United States declined to the midrange, leaving a strong
positive west-to-east gradient in CVD mortality.
Recently, new maps of CHD mortality by county for US women were published.25 These age-adjusted data again show striking variation by geographic region; the differences in CHD mortality between the counties with the lowest and highest rates are >3-fold. Again, a west-to-east gradient is observed, with a strong clustering of high CHD rates in the Mississippi Delta, in Appalachia and the Ohio River Valley, and in the Piedmont areas of Georgia, South Carolina, and North Carolina. Some areas, such as Mississippi, may actually have experienced increasing CHD mortality rates since the late 1980s. Those areas currently left with high CHD mortality are frequently characterized as rural and poor.
A more dynamic picture is available for trends in stroke. Howard et al26 calculated age-adjusted stroke mortality rates by race and ethnicity at the county level between 1968 and 1996. From these data, the percent decline in stroke mortality between 1968 and 1996 was determined. Statistical modeling of these data produced a calculated "floor" for stroke mortality rates and the distance to go to that floor. The results of these analyses yielded race/sex specific maps of stroke mortality for 1968, 1982, and 1996. These suggest that some states in the Southeast (eg, Georgia and Alabama) are no longer among those with the highest stroke mortality. Areas that now have high (compared with the rest of the United States) stroke mortality rates include Arkansas and Oregon/Washington. This splitting of the "stroke belt" and its movement to the South Central and Northwest regions of the United States demonstrates the dynamic changes in stroke mortality by region within only 3 decades.
Summary
For the United States as a whole, the CHD mortality
rate still seems to be declining, but at a slower rate than from 1970
to 1990. Stroke mortality rates have changed little in most areas since
1990. However, there are striking differences in levels and trends of
CVD rates by race/ethnicity, socioeconomic status, and
geography.
|
Recent Trends in Levels of CVD Risk Factors in the United States |
|---|
|
TopAbstractIntroductionRecent Trends in CVD...Recent Trends in Levels...Recent Trends in CVD...Strategic Overview of New...Areas Where New or...A More Effective Strategic...DiscussionReferences |
|---|
Changes in factors causally related to atherosclerotic CVD may explain these recent trends in mortality.27 This section explores recent trends in the major CVD risk factors, including cigarette smoking, dietary patterns, physical inactivity, obesity, blood pressure, serum lipids and lipoproteins, and diabetes. Trends are described in the US population as a whole and for population subgroups, especially race/ethnic groups, socioeconomic status levels, and children (when data are available).
Trends in Tobacco Use
Cigarette consumption on a per-capita basis declined
from 1964, the date of the issue of the First Surgeon General’s Report
on Smoking, when >40% of adults smoked, until 
1990. Nonetheless,
nearly 180 000 deaths from CVD were attributed to tobacco use in 1990.
Trends since 1990 suggest that smoking prevalence has reached an
asymptote, at which 25% of the US population continues to smoke on
a daily basis.28 Trends by
socioeconomic status, as measured by educational attainment, indicate a
greater reduction in smoking prevalence among those with some college
or a college degree, resulting in a substantial widening of the
gradient across educational strata since 1974. However, a lack of
further reduction in smoking prevalence seems to be present across all
educational strata. Smoking trends by race/ethnic groups parallel those
of the US population as a whole, but smoking prevalence rates vary
markedly by race/ethnic group and sex. Native American men and women
seem to have the highest prevalence rates. The rates of smoking remain
higher in men than in women. The lowest rates of smoking are found in
Hispanic and Asian women. For most groups, however, there seems to be a
flattening in the decline of smoking rates since 1990.
Trends in children are especially informative, because most dependent smokers begin smoking regularly before graduating from high school. Adolescent smoking prevalence, therefore, may serve as a predictor of future patterns of adult smoking. Smoking prevalence in 9th and 10th graders, in both boys and girls, increased from 1993 to 1997. By 12th grade, there is little difference in the rates of smoking between boys and girls, with a prevalence of 20% for both sexes.
Recent Dietary Trends
Dietary patterns in the United States over the past 30
years have been estimated using National Health and Nutrition
Examination Surveys (NHANES I, II, III), by US Department of
Agriculture Nationwide Food Consumption Surveys and Continuing Survey
of Food Intakes by Individuals, and by special surveys of local
populations.29 Continued
changes to improve dietary intake methodology make it difficult to
estimate trends in nutrient intake with confidence. Nevertheless, these
data, taken in aggregate, suggest that total fat consumption in grams
per day between the 1970s and 1990s has been stable or somewhat higher,
with a decrease as a percent of
calories.30 Estimated
carbohydrate intake has increased in parallel with the decrease in
percent of calories as total fat. Saturated fat consumption over this
period has fallen as a proportion of calorie intake, and dietary
cholesterol has been reduced by a fifth. These data are consistent with
decreased serum cholesterol levels over the same period.
Evaluation of trends of specific foods in the food supply shows that estimated intake of beer and wine has increased.31 Other shifts in food intake have occurred.29 32 There were reductions in the consumption of red meat, eggs, and whole milk between 1970 and 1997 and increases in the consumption of soda, grains, sweeteners, cheese, and fats and oils. Some of these changes may reflect changes in the way dietary data are collected.31 However, changes in nutrient and food intake may reflect the fact that consumers are not controlling the preparation of their meals. An increasing proportion of foods are prepared away from home; the proportion increased from 16% in 1977 through 1978 to 29% in 1995.33
Recent Trends in Levels of Leisure Time
Physical Activity
Participation in regular leisure time physical activity
in the United States can be estimated from 3 national surveys of adults
(National Health Interview Survey, NHANES, and the Behavioral Risk
Factor Surveillance
System).34 35
Data from 1996 suggest that only 28% of adults meet the recommended
levels of moderate or vigorous leisure time physical activity, and 29%
report no regular physical activity outside their work. The prevalence
of physical inactivity increases with age, is higher in women than men,
and is highest in black and Hispanic groups. There is a striking
gradient of physical inactivity by education; the prevalence of
physical inactivity in persons not graduating from high school is 2.5
times greater than that of college graduates. Physical inactivity is
highest in rural areas, especially those in the South and West. Over
the past 15 years, there have been only minor changes in leisure time
physical activity reported, although national surveillance data do not
include all types of physical activity (eg, occupational,
transportation) to verify population trends in total physical
activity.
As assessed by the Youth Risk Behavior Survey, 72% of high school boys and 54% of high school girls reported vigorous physical activity for at least 20 minutes 3 or more days per week. Attendance at daily physical education classes fell between 1991 and 1997 from 41% to 28%. White adolescents had higher rates of vigorous physical activity than black or Hispanic adolescents (67% versus 54% and 60%, respectively).
Recent Trends in the Prevalence of
Overweight and Obesity
Overweight and obesity are currently defined by body
mass index [weight in kilograms/(height in
meters)2]. A body mass index of 25 to 29.9
defines overweight, and one 
30 defines obesity. Current estimates
from NHANES III for US adults aged 20 to 74 years identify 60% of
men and 50% of women as being overweight, with 20% of men and 25%
of women being
obese.36 37 The
prevalence of overweight and obesity is higher in Hispanic men than in
non-Hispanic white or black men and is higher in both black women and
Hispanic women than in non-Hispanic white women. The prevalence of
overweight is inversely related to education or income in women of all
ethnic groups. For men, however, the pattern is opposite, with greater
obesity at higher levels of income. The prevalence of overweight is
13% to 15% in children 6 to 12 years of age and 11% to 12% in those
aged 12 to 17 years. Mexican-American boys have a higher
prevalence of overweight than black or white boys, and Mexican-American
and black girls have a higher prevalence of overweight than white
girls.
The trend in obesity increased strikingly from 1980 to 1994.37 Although the prevalence of overweight increased slightly between 1960 and 1994, a large increase in the prevalence of obesity in both men and women has been observed in the most recent data available from 1994. Parallel trends are seen in children (both in those aged 6 to 11 years and those aged 12 to 17 years). Although the prevalence of overweight increased with each year between 1963 and 1994, the large increase, especially in those aged 12 to 17 years, occurred between 1980 and 1994. The prevalence of overweight and obesity seems to have increased in all educational strata over this period of time.
Trends in Blood Pressure and
Hypertension
Hypertension remains a common condition in the United
States; it affects >43 million Americans and has an estimated
age-adjusted prevalence of 26% in adult males and of 22% in adult
females.38 39
Blacks have long been known to have the highest prevalence. Of the 43
million estimated hypertensives in the United States, >20 million are
not treated. Of the remaining 23 million treated hypertensives, an
estimated 12 million are thought not to be controlled (systolic blood
pressure <140 mm Hg and diastolic blood pressure <90 mm Hg); thus,
only 11 million of 43 million hypertensives are both treated and
controlled.
Although good progress was made in reducing the prevalence of high blood pressure in the 1970s and 1980s, the levels of awareness, treatment, and control apparently reached a plateau around 1990.38 40
Trends in Serum Lipids
Measurements of serum total cholesterol from
representative samples of the US population are available from NHANES
I, II, and III
(Table 3).41 42
These show considerable progress until around 1994 in reaching Year
2000 objectives of a serum total cholesterol 
200 mg/dL and 20% of
the adult population with a total cholesterol 240 mg/dL.
Progress can be seen in all race/sex groups and in all educational
strata, suggesting a change in population determinants of serum
cholesterol, such as the saturated fat and cholesterol content of the
US diet, despite the increase in the prevalence of
overweight.30 43
Although Asians, Native Americans, and Hispanics have lower total
cholesterol levels than non-Hispanic whites, there are clear gaps in
national data for all racial and ethnic groups, as well as for
geographic areas.
|
Trends in Type-2 Diabetes
Type-2 diabetes is a major contributor to CVD morbidity
and mortality in the United
States.44 Even before the
new, lower threshold of fasting blood glucose for the diagnosis of
diabetes, there was evidence that the prevalence of diagnosed cases of
type-2 diabetes had increased in recent years; it may now approach 7%
of US adults. The Behavioral Risk Factor Surveillance
System45 collected
self-reported data on physician-diagnosed diabetes. Age-adjusted
prevalence rates seem to have increased strikingly from 1995 to 1998 in
all race/ethnic groups, with increases ranging from 14% to 28%
(Table 4). A strong, inverse gradient by education was
observed, but large increases in diabetes prevalence seem to have
occurred in college-educated strata. In addition, it is estimated that
a large proportion (up to half) of cases of type-2 diabetes have not
been diagnosed, making these trends even more ominous. These sharply
rising prevalence rates are consistent with local serial surveys in
Rochester, Minnesota46 and
San Antonio, Texas47 between
1945 and 1990. The increase in the prevalence in diabetes does not seem
to be due to increased survival; rather, an increase in incidence
largely accounts for the increased prevalence. The incidence in both
Mexican Americans and non-Hispanic whites in San Antonio tripled from
1987 to
1996.47
|
Summary
Trends in levels of CVD risk factors are, to a great
extent, consistent with a slowing of the decline in population risk.
Prevalence rates of many risk factors, such as smoking, dietary
saturated fat and cholesterol, serum cholesterol, and hypertension,
fell until 1990; however, since then, there has been little or no
progress, at least in smoking prevalence, physical inactivity, and
hypertension control. Moreover, there are several trends suggesting an
increase in population risk, including greater dietary intake of
calories, a rapid rise in obesity prevalence, and a striking increase
in the prevalence of type-2 diabetes. Taken in aggregate, trends in
risk factors since 1990 do not seem to be heading toward a reduced risk
of CVD for Americans.
|
Recent Trends in CVD Preventive Services in the United States |
|---|
|
TopAbstractIntroductionRecent Trends in CVD...Recent Trends in Levels...Recent Trends in CVD...Strategic Overview of New...Areas Where New or...A More Effective Strategic...DiscussionReferences |
|---|
Trends in Population-Wide Interventions to Promote Healthy Lifestyles
The realization that widespread dietary habits, physical inactivity patterns, and tobacco use were associated with population-wide CVD began in the 1950s and was confirmed by studies such as the Seven Countries Study.48 This led to the concept that CVD prevention should be implemented at the population level. National efforts to make the US population aware of CVD and to educate health professionals about CVD prevention were initiated in the 1950s and 1960s with the issuance of formal statements and reports, such as the 1961 American Heart Association Diet Report, the 1964 Surgeon General’s report on smoking, and the 1970 Report of the Inter-Society Commission for Heart Disease Resources.49
Studies of community-wide interventions for CVD control were initiated in Finland50 and the United States51 in the early 1970s. These have been expanded to include schools, religious organizations, and worksites.52 An increasing number of public and private efforts have addressed CVD prevention issues on a national, regional, or local basis since the mid-1980s. As an example of efforts in the voluntary health sector, the American Heart Association developed an extensive series of materials and programs directed at population groups at worksites and schools, at consumers, and at subgroups such as women. At the federal level, the National High Blood Pressure Education Program, the National Cholesterol Education Program, the Obesity Education Initiative, and other programs have sought, through education and mass media, to increase awareness, treatment, and control for major CVD risk factors and to promote population-wide adoption of healthful lifestyles.
Since the early 1980s, public health agencies at the state level have received funding for CVD control through the Preventive Health and Health Services block grants. About 75% of block grant funding goes for chronic disease control, and all states currently receive block grant funds for CVD prevention. However, state funding for CVD control is not comparable to CVD’s burden on the population. For example, a survey of state health departments in 1989 revealed only 3% of total spending for health programs was devoted to all chronic diseases, violence, and injury prevention. In November 1998, the US Congress allocated funds to create a national CVD prevention program at the Centers for Disease Control and Prevention. This allocation currently stands at $16 million and funds programs in 11 states. The Centers for Disease Control and Prevention also has tobacco control programs in 33 states, statewide diabetes programs in 50 states, and school health programs on tobacco-use prevention, nutrition, and physical activity in 12 states. All states currently have programs in place to regulate promotion and access to tobacco and to control indoor environmental tobacco smoke.
In summary, national, population-based CVD prevention programs have increased in the past 15 years, but their extent and effectiveness are unknown. The impact of these programs on underserved and other high-risk subpopulations is also poorly described.
Trends in the Usage of Clinical Interventions
for Primary Prevention
Primary care physicians can play a central role in the
detection and management of CVD risk factors, including adverse eating,
drinking, and activity habits; smoking; hyperlipidemia; hypertension;
diabetes; and atrial fibrillation (a risk factor for thromboembolic
stroke). Surveys about physician attitudes, practice behaviors, and
patient-centered outcomes have been published over the past 30
years.
For cigarette smoking, >80% of physicians recognize the importance of smoking cessation counseling and have done so for >20 years. However, various studies have shown that less than half routinely counseled their patients during the 1980s and 1990s.53 54 Physicians acknowledge that hyperlipidemia is an important CVD risk factor, and screening for this condition has increased considerably; however, less than half of patients are treated.43 55 56 57 Similarly, physicians demonstrate an increase in their knowledge of high blood pressure as a major CVD risk factor, and screening for high blood pressure increased in the 1980s to >80% of adults.39 Treatment has also increased, but in the 1990s, only half of hypertensive patients received treatment from their physicians.39 58 Screening for diabetes also lagged in the 1980s and 1990s, with fewer than 50% of physicians routinely screening for this illness.59 60 61 Finally, despite numerous trials demonstrating the efficacy of anticoagulation to prevent stroke in patients with atrial fibrillation, less than half of patients were so treated.62 63
Taken in aggregate, these data show striking similarities among risk factors. Physician knowledge of the importance of risk factors and the efficacy of treatment is generally high, especially in the 1990s. However, the data consistently demonstrate that physicians use preventive interventions and risk behavior counseling less frequently than is recommended by expert panel guidelines and national standards of care.
Trends in Clinical Intervention for
Secondary Prevention
Patients with established CVD constitute one of the
highest risk groups. Secondary prevention involves identifying,
treating, and rehabilitating these patients to reduce their risks of
recurrence, decrease their need for interventional procedures, improve
their quality of life, and extend their overall survival. The American
Heart Association has identified the secondary preventive measures
generally accepted as
efficacious.64
The Health Care Financing Administration Cooperative Cardiovascular Project has examined the use of aspirin, ß-blockers, ACE inhibitors, and smoking advice in Medicare patients admitted with myocardial infarction nationwide.65 Remarkable heterogeneity is observed in the prescription rates of these proven secondary prevention strategies. For example, ß-blocker prescription rates vary by region, from <20% to >80% of patients with a myocardial infarction leaving the hospital with a ß-blocker prescribed. Areas in the Northeast and Midwest seem to have the highest rates of use, and the Southeast and South Central areas of the country have the lowest rates of ß-blocker use.
Another nationwide concern is the severe underuse of cardiac rehabilitation, despite its association with a 20% reduction in mortality. Approximately 15% to 30% of acute myocardial infarction patients receive cardiac rehabilitation.66 Reasons cited for nonparticipation include a lack of physician referral, poor patient motivation, and logistical or financial constraints.
Patients with CHD also infrequently receive the recommended levels of treatment for hyperlipidemia. An audit of 48 586 medical records of patients with CHD in 140 practices found only 44% had an LDL cholesterol measurement and only 25% had an LDL cholesterol level <100 mg/dL.67 Similarly, a study of 619 practices identified only 17% of CHD patients with an LDL cholesterol level <100 mg/dL.68
Revascularization procedures have increased annually for the past 15 years. However, several studies have identified disparities by race and sex in rates of cardiac catheterization, coronary bypass graft surgery, and percutaneous transluminal coronary artery interventions.69 70 71 Angioplasty and bypass surgery rates correlate with catheterization rates. Large geographic variations in the rates of these services exist, suggesting that factors other than disease incidence account for this variation.
Finally, congestive heart failure continues to be a major disease burden; it is the most common cause for hospital admission under the Medicare program. Rates of readmission in the 30 days after discharge are estimated at 18% to 25%. Guidelines for treatment, including use of diuretics and ACE inhibitors, have been established.72 Despite this, there is abundant evidence for undertreatment. For example, 5 studies have demonstrated only 10% to 50% of patients receive the recommended doses of ACE inhibitors.73 74 75 76 77
Summary
There is evidence for considerable activity in
population-wide prevention, primary prevention for higher risk people,
and secondary prevention. Given the magnitude of CVD as a health
problem, more can and should be done for population-based primary
prevention. Within the healthcare sector, fewer than 50% of patients
will reliably have their risk factors assessed, treated, or controlled.
Similar disparities are observed in secondary prevention, despite
widely accepted guidelines, numerous clinical trials, and favorable
cost-effectiveness studies. These data point to numerous gaps in our
efforts to use available, proven interventions to control CVD. Few data
are available on trends in these measures or in levels of disparity by
race/ethnic, socioeconomic, or geographic
group.
|
Strategic Overview of New Approaches to CVD Control |
|---|
|
TopAbstractIntroductionRecent Trends in CVD...Recent Trends in Levels...Recent Trends in CVD...Strategic Overview of New...Areas Where New or...A More Effective Strategic...DiscussionReferences |
|---|
Much has been accomplished to relieve the burden of CHD, stroke, and peripheral arterial disease on the American people, with huge declines in CVD mortality since the 1960s. However, the CVD mortality decline seems to have slowed. Moreover, the mortality gap between certain population subgroups, defined by race/ethnicity, socioeconomic status, and geography, and the rest of the US population continues to increase. Parallel to these trends is evidence that a number of deleterious risk behaviors have either stopped improving or even worsened, which forecasts difficulty in achieving further declines in CVD incidence. CVD prevention can presently be characterized overall as possessing a wealth of knowledge about cause, diagnosis, prevention, and treatment but only limited effectiveness in applying and implementing that knowledge.
Therefore, to restore and even accelerate the decline in CVD mortality and to achieve the Healthy People 2010 Objectives for CVD, the National Conference on CVD Prevention concluded that the essential strategy for the prevention and control of this epidemic should be as follows.
- A
comprehensive, population-wide approach that especially emphasizes
primary risk factor prevention and risk factor detection and
management.
- Attention to all population subgroups, especially
those at higher risk.
- Mobilization of the considerable multifaceted
resources needed to implement this strategy
effectively.
As expressed by David Satcher, MD, PhD, Assistant Secretary for Health and the US Surgeon General, the major goals of the Healthy People 2010 Objectives are to increase the span of healthy life and the quality of life and to reduce disparities in health status on the basis of race/ethnicity, socioeconomic status, and geography. To do this, a more balanced community health system is needed, with emphasis on the promotion of healthy lifestyles in all parts of the community, and a research agenda that values basic, clinical, and population-based investigation.
|
Areas Where New or Better Data Are Needed to Attain the Year 2010 Health Objectives, as Part of a Strategic Research Agenda for the 21st Century |
|---|
|
TopAbstractIntroductionRecent Trends in CVD...Recent Trends in Levels...Recent Trends in CVD...Strategic Overview of New...Areas Where New or...A More Effective Strategic...DiscussionReferences |
|---|
On the basis of the review of trends in CVD mortality, risk factors, and deleterious health behaviors and the provision of preventive services, 8 recommendations for new areas of research and development were put forth by the National Conference on CVD Prevention.
1. Apply established theory and prior experience in community studies and test interventions involving modern forms of health communication, environmental change, and policy.
2. Explore opportunities afforded by managed care and other computerized medical record linkage systems for monitoring trends in mortality, morbidity, risk factors, and preventive services.
3. Design community interventions with shorter durations and intermediate end points for widespread implementation; these should include smaller, high-risk population subgroups, as defined by race/ethnicity, socioeconomic status, or geography.
4. Establish a national surveillance system for CVD that will:
a. Provide adequate data to monitor levels and trends in population subgroups, as defined by race/ethnicity, socioeconomic status, and geography.
b. Allow differences within the population in mortality, morbidity (including congestive heart failure), incidence, and risk factor levels to be better understood.
5. Design research to improve risk-factor detection and management in primary care settings based on a better understanding of the behavior at the patient, provider, and organizational levels and, specifically, acquire knowledge about the intensity of interventions required to activate behavior change, better measures of outcomes to monitor these behavior changes, and means to maintain beneficial behavior changes.
6. Design research in healthcare organizations to understand better the role of incentives in preventive care delivery, the opportunities in managed care and other "systems approaches," the potential role of multidisciplinary teams, and the promise of technological advances to improve data collection, service delivery, and cost effectiveness.
7. Seek greater understanding of physician and patient factors that affect adherence to prevention guidelines, and expand secondary prevention with risk factor management that is pathophysiologically grounded, evidence-based, and cost-effective.
8. Expand the identification of susceptible individuals using new measures of premorbid disease.
|
A More Effective Strategic Agenda for CVD Prevention Programs and Policies as a Means to Achieve the Healthy People 2010 Objectives |
|---|
|
TopAbstractIntroductionRecent Trends in CVD...Recent Trends in Levels...Recent Trends in CVD...Strategic Overview of New...Areas Where New or...A More Effective Strategic...DiscussionReferences |
|---|
Although research will provide improved tools and strategies for application to the problem of CVD, the existing wealth of knowledge is being applied with limited effectiveness. To address this, 7 recommendations were put forth by the National Conference on CVD Prevention as a way to meet the challenges raised by the current trends in CVD.
- Clearly define and fully coordinate the
leadership of the CVD control efforts at the population, primary care,
and secondary prevention/rehabilitation levels.
- Cultivate enhanced collaborations and
partnerships for population-based programs (eg, state and local health
departments, academia, voluntary health organizations, public advocacy
groups, employers, unions, religious organizations, schools, various
industries, etc), in primary care (eg, physicians, nurses, dietitians
and nutritionists, physiatrists, health educators, other health
professionals, voluntary health organizations, pharmaceutical
industries, third-party payers, and managed care organizations), and in
secondary prevention/rehabilitation (eg, specialty professional
organizations, voluntary health organizations, pharmaceutical and
device manufacturers, hospitals, and third-party
payers).
- Expand the work force trained in CVD prevention at
the community, primary care, and secondary prevention/rehabilitation
levels.
- Implement new strategies to reduce the risks of
populations and individuals through policy and environmental change at
the population level (eg, nutrition, physical activity, and tobacco
control), in primary care systems (eg, reorganization of care teams and
use of nonphysician professionals and self-help programs), and by
secondary prevention/rehabilitation providers (eg, inpatient care
protocols, nurse case managers, and more accessible rehabilitation
programs).
- Develop a national CVD surveillance system, which
includes measures of incidence, morbidity/disability, and use of
preventive services in addition to current mortality and risk-factor
prevalence data, with the capability to identify trends in subgroups,
including higher risk subgroups, as defined by race/ethnicity,
socioeconomic status, and geography, for use in planning and evaluation
(note: this is similar to the first recommendation for research and
development).
- Explore new systems to evaluate the
performance of preventive services at the population, primary care, and
secondary prevention levels for the purposes of program planning and
evaluation, accountability of responsible providers, and motivation of
populations and individuals.
- Create new mechanisms to support existing prevention
programs and to provide resources for new initiatives and incentives
for system, provider, and individual behavior change to create a
community and healthcare system more balanced toward
prevention.
|
Discussion |
|---|
|
TopAbstractIntroductionRecent Trends in CVD...Recent Trends in Levels...Recent Trends in CVD...Strategic Overview of New...Areas Where New or...A More Effective Strategic...DiscussionReferences |
|---|
This report intends to provide a current picture of cardiovascular health in the United States at the end of the 20th century. The striking declines in CHD since 1960 and in stroke since 1920 have led some to conclude that the CVD epidemic will disappear, possibly without further investment of effort or resources or without the development of enhanced prevention and treatment strategies. At the very least, recent trends suggest that CVD patterns in the United States are much more complex than previously appreciated. Mortality declines do not necessarily equate with reduced incidence; on the contrary, some population-based studies suggest that incidence has not changed since the late 1980s.78 The resulting increase in prevalence due to reduced case-fatality rates has resulted in higher levels of disability and healthcare cost from CVD. A more pessimistic view would predict an actual increase in incidence on the basis of deleterious risk factor trends and continued high levels of mortality as many CVD patients eventually die of heart failure and the long-term sequelae of stroke.
The core strategy implied in the research and programmatic recommendations of the National Conference on CVD is to target incidence reduction as the key to CVD control through the prevention of risk factors and prompt, sustained, and effective treatment of risk factors once they develop. Trends in risk behaviors suggest that we still have large deficits in our knowledge of determinants of population behavior. Gaps in the implementation of widely accepted treatment guidelines suggest that improvement in healthcare provider behaviors remain an elusive target. Although significant questions need exploration, a number of programs can be advocated on the basis of what is already known. The allocation of resources for such programs is a key issue, especially for a disease that is already a leading cost of direct and indirect health expenditures.
Not to be forgotten in these discussions is one fundamental reason for disappointing trends in mortality, risk factors, and preventive services: the disparities existing in the United States between the affluent and the poor. An examination of mortality, risk-factor prevalence, and use of preventive services identifies room for improvement even in the affluent. However, it may be difficult or impossible to achieve national goals for CVD control by efforts that simply widen the gap between groups defined by race/ethnicity, socioeconomic status, or geography. Therefore, any research or programmatic strategies must involve all segments of the US population, with enhanced efforts to remove differences in risk behaviors, preventive care, and morbidity and mortality in the disadvantaged.
|
Acknowledgments |
|---|
The authors thank Debra Graham and Kecia Brown for coordinating the National Conference on CVD Prevention and Kathy Bohn for assistance in manuscript preparation.
|
Footnotes |
|---|
%From Loyola University Medical Center, Chicago, Ill (R.C.); the National Heart, Lung, and Blood Institute, Bethesda, Md (J.C., P.D-N., L.F., G.M., T.T.); Stanford University, Palo Alto, Calif (S.P.F.); the National Institute on Aging, Bethesda, Md (R.H.); the Centers for Disease Control and Prevention, Atlanta, Ga (G.H.); the National Institute of Neurological Disease and Stroke, Bethesda, Md (J.M.); University of Minnesota, St. Paul, Minn (P.M.); Columbia and Cornell Universities, New York, NY (L.M.); University of Rochester, Rochester, NY (T.P.); Northwestern University Medical School, Chicago, Ill (J.S.); and the Agency for Healthcare Research and Quality, Rockville, Md (D.S.).
|
References |
|---|
|
TopAbstractIntroductionRecent Trends in CVD...Recent Trends in Levels...Recent Trends in CVD...Strategic Overview of New...Areas Where New or...A More Effective Strategic...DiscussionReferences |
|---|
1. Howson CP, Reddy KS, Ryan TJ, et al, eds. Control of Cardiovascular Disease in Developing Countries: Research, Development, and Institutional Strengthening. Washington, DC: National Academy Press; 1998.
2. Healthy People 2010: Conference Edition. Washington, DC: US Department of Health and Human Services; 2000. Available at: http://www health gov/healthypeople/Document/default/htm. Accessed August 2000.
3. U.S. House. House Report 105-635 (p 65). Accompanies: Omnibus Consolidated and Energency Supplemental Appropriations Act. Pub L No 105-277, 112 Stat 2681 (October 21, 1998).
4. Havlik RJ, Feinleib M, eds. Proceedings of the Conference on the Decline in Coronary Heart Disease Mortality. Washington, DC: US Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health; 1979. NIH Publication No 79-1610.
5. Higgins MW, Luepker RV, eds. Trends in Coronary Heart Disease Mortality: The Influence of Medical Care. New York: Oxford University Press; 1988.
6. Higgins MW, Luepker RV. Trends and determinants of coronary heart disease mortality: international comparisons. Int J Epidemiol. 1989;18(suppl I):S1–S232.
7. Hoyert DL, Kochanek KD, Murphy SL. Deaths: final data for 1997. In: National Vital Statistics Reports. Hyattsville, Md: National Center for Health Statistics; 1999. DHHS Publication Number 99-1120.
8. Morbidity and Mortality: 1998 Chart Book on Cardiovascular, Lung, and Blood Diseases. Bethesda, Md: National Institutes of Health: National Heart, Lung, and Blood Institute; 1998.
9. Morbidity and Mortality: 2000 Chart Book on Cardiovascular, Lung, and Blood Diseases. Bethesda, Md: National Institutes of Health: National Heart, Lung, and Blood Institute; 2000.
10. Compressed Mortality Database, 1979–1998. Centers for Disease Control and Prevention webpage. Available at: http://wonder.cdc.gov/mortsql.shtml. Accessed August 2000.
11. Sondik E. Cardiovascular trends in the United States. Paper presented at: National Conference on CVD Prevention; September 27–29, 1999; Bethesda, Md.
12.
Gillum RF, Sempos
CT. The end of the long-term decline in stroke mortality in the United
States? Stroke. 1997;28:1527–1529.
13.
Shahar E,
McGovern PG, Pankow JS, et al. Stroke rates during the 1980s: the
Minnesota Stroke Survey. Stroke. 1997;28:275–279.
14.
Cooper R, Sempos
C, Hsieh SC, et al. Slowdown in the decline of stroke mortality in the
United States, 1978–1986.
Stroke. 1990;21:1274–1279.
15. Mensah GA, Croft JB, Haldeman GA, et al. Congestive heart failure trends in population subgroups. Paper presented at: National Conference on CVD Prevention; September 27–29, 1999; Bethesda, Md.
16.
Sempos C, Cooper
R, Kovar MG, et al. Divergence of the recent trends in coronary
mortality for the four major race-sex groups in the United States.
Am J Public Health. 1988;78:1422–1427.
17. Liao Y, Cooper RS. Continued adverse trends in coronary heart disease mortality among blacks, 1980–91. Public Health Rep. 1995;110:572–579.[Medline] [Order article via Infotrieve]
18. Barnett E, Halverson J. Disparities in premature coronary heart disease mortality by region and urbanicity among black and white adults ages 35–64, 1985–1995. Public Health Rep. 2000;115:52–64.[Medline] [Order article via Infotrieve]
19.
Kaplan GA, Keil
JE. Socioeconomic factors and cardiovascular disease: a review of the
literature. Circulation. 1993;88:1973–1998.
20. Report of the Conference of Socioeconomic Status and Cardiovascular Health and Disease, November 6–7, 1995. Washington, DC: National Institutes of Health: National Heart, Lung, and Blood Institute; 1995.
21.
Wing S, Barnett
E, Casper M, et al. Geographic and socioeconomic variation in the onset
of decline of coronary heart disease mortality in white women.
Am J Public Health. 1992;82:204–209.
22. Cooper R, Casper M, Barnett E. Trends in heart disease by race/ethnicity, socioeconomic status and geography. Paper presented at: National Conference on CVD Prevention; September 27–29, 1999; Bethesda, Md.
23.
Feldman JJ, Makuc
DM, Kleinman JC, et al. National trends in educational differentials in
mortality. Am J Epidemiol. 1989;129:919–933.
24.
Pappas G, Queen
S, Hadden W, et al. The increasing disparity in mortality between
socioeconomic groups in the United States, 1960 and 1986.
N Engl J Med. 1993;329:103–109.
25. Casper ML, Barnett E, Halverson JA, et al. Women and Heart Disease: An Atlas of Racial and Ethnic Disparities in Mortality. Morgantown, WV: Office for Social Environment and Health Research, West Virginia University; 1999.
26. Howard G, Howard VJ, Katholi C, et al. The decline in stroke mortality: an analysis of temporal patterns by gender, ethnicity, and geographic region. Paper presented at: National Conference on CVD Prevention; September 27–29, 1999; Bethesda, Md.
27. Byers T, Anda R, McQueen D, et al. The correspondence between coronary heart disease mortality and risk factor prevalence among states in the United States, 1991–1992. Prev Med. 1998;27:311–316.[Medline] [Order article via Infotrieve]
28. Fiore M. Trends in tobacco use. Paper presented at: National Conference on CVD Prevention; September 27–29, 1999; Bethesda, Md.
29. Kris-Etherton P. Dietary trends. Paper presented at: National Conference on CVD Prevention; September 27–29, 1999; Bethesda, Md.
30. Ernst ND, Sempos CT, Briefel RR, et al. Consistency between US dietary fat intake and serum total cholesterol concentrations: the National Health and Nutrition Examination Surveys. Am J Clin Nutr. 1997;66(suppl 4):965S–972S.
31. Tippett KS, Cleveland LE. How current diets stack up. In: America’s Eating Habits: Changes and Consequences. Washington, DC: Economic Research Service; 1999. Agriculture Information Bulletin 750.
32. Putnam J, Gerrior S. Americans consuming more grains and vegetables, less saturated fat. Food Rev. 1998;20(3):2–12.
33. Lin BH, Guthrie J, Frazao E. Popularity of dining out presents barrier to dietary improvements. Food Rev. 1999;21(2):2–10.
34. Pratt M. Levels of physical activity and inactivity in children and adults in the United States. Paper presented at: National Conference on CVD Prevention; September 27–29, 1999; Bethesda, Md.
35. Physical Activity and Health: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion; 1996.
36. Kumanyika S. Overweight and obesity prevalence and trends in the US population. Paper presented at: National Conference on CVD Prevention; September 27–29, 1999; Bethesda, Md.
37. Clinical Guidelines and Identification, Evaluation, and Treatment of Overweight, and Obesity in Adults: The Evidence Report. Bethesda, Md: National Institutes of Health: National Heart, Lung, and Blood Institute in cooperation with the National Institute of Diabetes and Digestive and Kidney Diseases; 1998. NIH Publication No. 98-4083.
38.
Burt VL, Cutler
JA, Higgins M, et al. Trends in the prevalence, awareness, treatment,
and control of hypertension in the adult US population: data from the
Health Examination Surveys, 1960 to 1991.
Hypertension. 1995;26:60–69.
39. Ferdinand KC. Trends in levels of CVD risk factors in the US population and subgroups: blood pressure. Paper presented at: National Conference on CVD Prevention; September 27–29, 1999; Bethesda, Md.
40. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, Md: National Institutes of Health: National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program; 1997. NIH Publication No. 98-4080.
41. Sempos CT, Carroll MD. Recent US. trends in serum lipids: a minority health focus. Paper presented at: National Conference on CVD Prevention; September 27–29, 1999; Bethesda, Md.
42.
Johnson CL,
Rifkind BM, Sempos CT, et al. Declining serum cholesterol levels among
US adults: the National Health and Nutrition Examination
Surveys. JAMA. 1993;269:3002–3008.
43.
Cleeman JI,
Lenfant C. The National Cholesterol Education Program: progress and
prospects. JAMA. 1998;280:2099–2104.
44. Stern MP. Secular trends in type 2 diabetes prevalence, incidence, and survival. Paper presented at: National Conference on CVD Prevention; September 27–29, 1999; Bethesda, Md.
45. Behavioral Risk Factor Surveillance System. National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention website. Available at: http://www2.cdc.gov/nccdphp/brfss/index.asp. Accessed August 2000.
46.
Leibson CL,
O’Brien PC, Atkinson E, et al. Relative contributions of incidence and
survival to increase prevalence of adult-onset diabetes mellitus: a
population-based study. Am J
Epidemiol. 1997;146:12–22.
47.
Burke JP,
Williams K, Gaskill SP, et al. Rapid rise in the incidence of type 2
diabetes from 1987 to 1996: results from the San Antonio Heart Study.
Arch Intern Med. 1999;159:1450–1456.
48. Keys AB. Seven Countries: A Multivariate Analysis of Death and Coronary Heart Disease. Cambridge, Mass: Harvard University Press; 1980.
49. Report of the Inter-Society Commission for Heart Disease Resources: Prevention of cardiovascular disease: primary prevention of the atherosclerotic diseases. Circulation. 1970;42:A55–A95.
50. Puska P, Tuomilehto J, Nissanen A, et al. The North Karelia Project: 20 Year Results and Experiences. Helsinki: Helsinki University Printing House; 1995.
51. Farquhar JW, Maccoby N, Wood PD, et al. Community education for cardiovascular health. Lancet. 1977;1:1192–1195.[Medline] [Order article via Infotrieve]
52. Stone EJ, Pearson TA, eds. Community trials for cardiopulmonary health: directions for public health practice, policy, and research. Ann Epidemiol. 1997;7 (suppl):S1–S124.
53.
Thorndike AN,
Rigotti NA, Stafford RS, et al. National patterns in the treatment of
smokers by physicians. JAMA. 1998;279:604–608.
54.
Cummings SR,
Stein MJ, Hansen B, et al. Smoking counseling and preventive medicine:
a survey of internists in private practices and a health maintenance
organization. Arch Intern Med. 1989;149:345–349.
55.
Frolkis JP,
Zyzanski SJ, Schwartz JM, et al. Physician noncompliance with the 1993
National Cholesterol Education Program (NCEP-ATPII) guidelines.
Circulation. 1998;98:851–855.
56.
Pieper RM, Arnett
DK, McGovern PG, et al. Trends in cholesterol knowledge and screening
and hypercholesterolemia awareness and treatment, 1980–1992: the
Minnesota Heart Survey. Arch Intern
Med. 1997;157:2326–2332.
57. Stafford RS, Blumenthal D, Pasternak RC. Variations in cholesterol management practices of US physicians. J Am Coll Cardiol. 1997;29:139–146.[Abstract]
58. Pavlik VN, Hyman DJ, Vallbona C. Hypertension control in multi-ethnic primary care clinics. J Hum Hypertens. 1996;10(suppl 3):S19–S23.
59. Cowie CC, Harris MI, Eberhardt MS. Frequency and determinants of screening for diabetes in the US. Diabetes Care. 1994;17:1158–1163.[Abstract]
60.
Streja DA, Rabkin
SW. Factors associated with implementation of preventive care measures
in patients with diabetes mellitus. Arch
Intern Med. 1999;159:294–302.
61. Zoorob RJ, Mainous AG 3rd. Practice patterns of rural family physicians based on the American Diabetes Association standards of care. J Community Health. 1996;21:175–182.[Medline] [Order article via Infotrieve]
62.
Stafford RS,
Singer DE. Recent national patterns of warfarin use in atrial
fibrillation. Circulation. 1998;97:1231–1233.
63. Mendelson G, Aronow WS. Underutilization of warfarin in older persons with chronic nonvalvular atrial fibrillation at high risk for developing stroke. J Am Geriatr Soc. 1998;46:1423–1424.[Medline] [Order article via Infotrieve]
64. Smith SC Jr, Blair SN, Criqui MH, et al. Preventing heart attack and death in patients with coronary disease. Circulation. 1995;92:2–4.
65.
Marciniak TA,
Ellerbeck EF, Radford MJ, et al. Improving the quality of care for
Medicare patients with acute myocardial infarction: results from the
Cooperative Cardiovascular Project.
JAMA. 1998;279:1351–1357.
66. Cardiac Rehabilitation Guideline Panel. Cardiac Rehabilitation. Washington, DC: US Agency for Health Care Policy and Research and National Heart, Lung, and Blood Institute; 1995. AHCPR Publication No 96–0672.
67. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1999;83:1303–1307.[Medline] [Order article via Infotrieve]
68.
Pearson TA,
Laurora I, Chu H, et al. The Lipid Treatment Assessment Project
(L-TAP): a multicenter survey to evaluate the percentages of
dyslipidemic patients receiving lipid-lowering therapy and achieving
low-density lipoprotein goals. Arch Intern
Med. 2000;160:459–467.
69. Gillum RF, Gillum BS, Francis CK. Coronary revascularization and cardiac catheterization in the United States: trends in racial differences. J Am Coll Cardiol. 1997;29:1557–1562.[Abstract]
70. Daumit GL, Hermann JA, Powe NR. Relation of gender and health insurance to cardiovascular procedure use in persons with progression of chronic renal disease. Med Care. 2000;38:354–365.[Medline] [Order article via Infotrieve]
71. Sheifer SE, Escarce JJ, Schulman KA. Race and sex differences in the management of coronary artery disease. Am Heart J. 2000;139:848–857.[Medline] [Order article via Infotrieve]
72. Packer M, Cohn JN, eds, on behalf of the membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure. Consensus recommendations for the management of chronic heart failure. Am J Cardiol. 1999;83(suppl 2A):1A–38A.
73. Luzier AB, DiTusa L. Underutilization of ACE inhibitors in heart failure. Pharmacotherapy. 1999;19:1296–1307.[Medline] [Order article via Infotrieve]
74. Gattis WA, Larsen RL, Hasselblad V, et al. Is optimal angiotensin-converting enzyme inhibitor dosing neglected in elderly patients with heart failure? Am Heart J. 1998;136:43–48.[Medline] [Order article via Infotrieve]
75. Roe CM, Motheral BR, Teitelbaum F, et al. Angiotensin-converting enzyme inhibitor compliance and dosing among patients with heart failure. Am Heart J. 1999;138:818–825.[Medline] [Order article via Infotrieve]
76.
Missouris CG,
MacGregor GA. The use of angiotensin-converting enzyme inhibitors in
the treatment of heart failure in hospital practice.
Postgrad Med J. 1997;73:409–411.
77. Luzier AB, Navsarikar A, Wilson MF, et al. Patterns of prescribing ACE inhibitors after myocardial infarction. Pharmacotherapy. 1999;19:655–660.[Medline] [Order article via Infotrieve]
78.
Goldberg
RJ, Yarzebski J, Lessard D, et al. A two-decades (1975 to 1995) long
experience in the incidence, in-hospital and long-term case-fatality
rates of acute myocardial infarction: a community-wide perspective.
J Am Coll Cardiol. 1999;33:1533–1539.
This article has been cited by other articles:
 |
|
 |
|
  S. R. Govil, G. Weidner, T. Merritt-Worden, and D. Ornish Socioeconomic Status and Improvements in Lifestyle, Coronary Risk Factors, and Quality of Life: The Multisite Cardiac Lifestyle Intervention Program Am J Public Health, July 1, 2009; 99(7): 1263 - 1270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Beckfield and N. Krieger Epi + demos + cracy: Linking Political Systems and Priorities to the Magnitude of Health Inequities--Evidence, Gaps, and a Research Agenda Epidemiol. Rev., June 9, 2009; (2009) mxp002v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Preis, S.-J. Hwang, S. Coady, M. J. Pencina, R. B. D'Agostino Sr, P. J. Savage, D. Levy, and C. S. Fox Trends in All-Cause and Cardiovascular Disease Mortality Among Women and Men With and Without Diabetes Mellitus in the Framingham Heart Study, 1950 to 2005 Circulation, April 7, 2009; 119(13): 1728 - 1735. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Gulliford and J. Charlton Is Relative Mortality of Type 2 Diabetes Mellitus Decreasing? Am. J. Epidemiol., February 15, 2009; 169(4): 455 - 461. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Rosenzweig, E. Ferrannini, S. M. Grundy, S. M. Haffner, R. J. Heine, E. S. Horton, and R. Kawamori Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3671 - 3689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Stephens, H. Braithwaite, L. Johnson, C. Harris, S. Katkowsky, and A. Troutman Cardiovascular risk reduction for African-American men through health empowerment and anger management Health Education Journal, September 1, 2008; 67(3): 208 - 218. [Abstract] [PDF]
|
|
|
|
|
|
J. Xie, E. Q. Wu, Z.-J. Zheng, P. W. Sullivan, L. Zhan, and D. R. Labarthe Patient-Reported Health Status in Coronary Heart Disease in the United States: Age, Sex, Racial, and Ethnic Differences Circulation, July 29, 2008; 118(5): 491 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Ussher and G. D. Lopaschuk The malonyl CoA axis as a potential target for treating ischaemic heart disease Cardiovasc Res, July 15, 2008; 79(2): 259 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A J Schulz, J S House, B A Israel, G Mentz, J T Dvonch, P Y Miranda, S Kannan, and M Koch Relational pathways between socioeconomic position and cardiovascular risk in a multiethnic urban sample: complexities and their implications for improving health in economically disadvantaged populations J Epidemiol Community Health, July 1, 2008; 62(7): 638 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Prisant, K. L. Thomas, E. F. Lewis, Z. Huang, G. S. Francis, W. D. Weaver, M. A. Pfeffer, J. J.V. McMurray, R. M. Califf, and E. J. Velazquez Racial Analysis of Patients With Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Treated With Valsartan, Captopril, or Both J. Am. Coll. Cardiol., May 13, 2008; 51(19): 1865 - 1871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Perry, A. G. Rosenfeld, and J. Kendall Rural Women Walking for Health West J Nurs Res, April 1, 2008; 30(3): 295 - 316. [Abstract] [PDF]
|
|
|
|
 |
|
 S Harding, M Rosato, and A Teyhan Trends for coronary heart disease and stroke mortality among migrants in England and Wales, 1979-2003: slow declines notable for some groups Heart, April 1, 2008; 94(4): 463 - 470. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Ford and S. Capewell Coronary Heart Disease Mortality Among Young Adults in the U.S. From 1980 Through 2002: Concealed Leveling of Mortality Rates J. Am. Coll. Cardiol., November 27, 2007; 50(22): 2128 - 2132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. W. Gregg, Q. Gu, Y. J. Cheng, K. M. Venkat Narayan, and C. C. Cowie Mortality Trends in Men and Women with Diabetes, 1971 to 2000 Ann Intern Med, August 7, 2007; 147(3): 149 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Loria, K. Liu, C. E. Lewis, S. B. Hulley, S. Sidney, P. J. Schreiner, O. D. Williams, D. E. Bild, and R. Detrano Early Adult Risk Factor Levels and Subsequent Coronary Artery Calcification: The CARDIA Study J. Am. Coll. Cardiol., May 22, 2007; 49(20): 2013 - 2020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Goff Jr, L. Brass, L. T. Braun, J. B. Croft, J. D. Flesch, F. G.R. Fowkes, Y. Hong, V. Howard, S. Huston, S. F. Jencks, et al. Essential Features of a Surveillance System to Support the Prevention and Management of Heart Disease and Stroke: A Scientific Statement From the American Heart Association Councils on Epidemiology and Prevention, Stroke, and Cardiovascular Nursing and the Interdisciplinary Working Groups on Quality of Care and Outcomes Research and Atherosclerotic Peripheral Vascular Disease Circulation, January 2, 2007; 115(1): 127 - 155. [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Pearson The Prevention Of Cardiovascular Disease: Have We Really Made Progress? Health Aff., January 1, 2007; 26(1): 49 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Lawler, H.-B. Kwak, W. Song, and J. L. Parker Exercise training reverses downregulation of HSP70 and antioxidant enzymes in porcine skeletal muscle after chronic coronary artery occlusion Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2006; 291(6): R1756 - R1763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kanjilal, E. W. Gregg, Y. J. Cheng, P. Zhang, D. E. Nelson, G. Mensah, and G. L. A. Beckles Socioeconomic Status and Trends in Disparities in 4 Major Risk Factors for Cardiovascular Disease Among US Adults, 1971-2002 Arch Intern Med, November 27, 2006; 166(21): 2348 - 2355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dewey, F. Teige, D. Schnapauff, M. Laule, A. C. Borges, K.-D. Wernecke, T. Schink, G. Baumann, W. Rutsch, P. Rogalla, et al. Noninvasive detection of coronary artery stenoses with multislice computed tomography or magnetic resonance imaging. Ann Intern Med, September 19, 2006; 145(6): 407 - 415. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Y. Gandhi, V. L. Roger, K. R. Bailey, P. J. Palumbo, J. E. Ransom, and C. L. Leibson Temporal Trends in Prevalence of Diabetes Mellitus in a Population-Based Cohort of Incident Myocardial Infarction and Impact of Diabetes on Survival Mayo Clin. Proc., August 1, 2006; 81(8): 1034 - 1040. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Whittle, N. R. Kressin, E. D. Peterson, M. B. Orner, M. Glickman, M. Mazzella, and L. A. Petersen Racial Differences in Prevalence of Coronary Obstructions Among Men With Positive Nuclear Imaging Studies J. Am. Coll. Cardiol., May 16, 2006; 47(10): 2034 - 2041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lynch, G. Davey Smith, S. Harper, and K. Bainbridge Explaining the social gradient in coronary heart disease: comparing relative and absolute risk approaches J Epidemiol Community Health, May 1, 2006; 60(5): 436 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Yang, L. D. Botto, J. D. Erickson, R. J. Berry, C. Sambell, H. Johansen, and J.M. Friedman Improvement in Stroke Mortality in Canada and the United States, 1990 to 2002 Circulation, March 14, 2006; 113(10): 1335 - 1343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ohlander, M. Vikstrom, M. Lindstrom, and K. Sundquist Neighbourhood non-employment and daily smoking: a population-based study of women and men in Sweden Eur J Public Health, February 1, 2006; 16(1): 78 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Taylor, J. T. Wright Jr, R. S. Cooper, B. M. Psaty, A. L. Taylor, J. T. Wright Jr, R. S. Cooper, and B. M. Psaty Importance of Race/Ethnicity in Clinical Trials: Lessons From the African-American Heart Failure Trial (A-HeFT), the African-American Study of Kidney Disease and Hypertension (AASK), and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Circulation, December 6, 2005; 112(23): 3654 - 3666. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Veazie, J. M. Galloway, D. Matson-Koffman, D. R. LaBarthe, J. N. Brownstein, M. Emr, E. Bolton, E. Freund Jr, R. Fulwood, J. Guyton-Krishnan, et al. Taking the Initiative: Implementing the American Heart Association Guide for Improving Cardiovascular Health at the Community Level: Healthy People 2010 Heart Disease and Stroke Partnership Community Guideline Implementation and Best Practices Workgroup Circulation, October 18, 2005; 112(16): 2538 - 2554. [Full Text] [PDF]
|
|
|
|
 |
|
 F Janssen and AE Kunst for The Netherlands Epidemiology and Demo Cohort patterns in mortality trends among the elderly in seven European countries, 1950-99 Int. J. Epidemiol., October 1, 2005; 34(5): 1149 - 1159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F Janssen, A Peeters, J P Mackenbach, A E Kunst, and for NEDCOM Relation between trends in late middle age mortality and trends in old age mortality--is there evidence for mortality selection? J Epidemiol Community Health, September 1, 2005; 59(9): 775 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The National Heart, Lung, and Blood Institute Work Major Clinical Trials of Hypertension: What Should Be Done Next? Hypertension, July 1, 2005; 46(1): 1 - 6. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Krumholz, E. D. Peterson, J. Z. Ayanian, M. H. Chin, R. F. DeBusk, L. Goldman, C. I. Kiefe, N. R. Powe, J. S. Rumsfeld, J. A. Spertus, et al. Report of the National Heart, Lung, and Blood Institute Working Group on Outcomes Research in Cardiovascular Disease Circulation, June 14, 2005; 111(23): 3158 - 3166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N.J.A. van Exel, M.A. Koopmanschap, W. Scholte op Reimer, L.W. Niessen, and R. Huijsman Cost-effectiveness of integrated stroke services QJM, June 1, 2005; 98(6): 415 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Bunch, S. C. Hammill, and R. D. White Outcomes After Ventricular Fibrillation Out-of-Hospital Cardiac Arrest: Expanding the Chain of Survival Mayo Clin. Proc., June 1, 2005; 80(6): 774 - 782. [Abstract] [PDF]
|
|
|
|
|
|
T. C. Lee, J. G. Hanlon, J. Ben-David, G. L. Booth, W. J. Cantor, P. W. Connelly, and S. W. Hwang Risk Factors for Cardiovascular Disease in Homeless Adults Circulation, May 24, 2005; 111(20): 2629 - 2635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Parekh, L. Zhang, B. A. Fivush, and M. J. Klag Incidence of Atherosclerosis by Race in the Dialysis Morbidity and Mortality Study: A Sample of the US ESRD Population J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1420 - 1426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. W. Gregg, Y. J. Cheng, B. L. Cadwell, G. Imperatore, D. E. Williams, K. M. Flegal, K. M. V. Narayan, and D. F. Williamson Secular Trends in Cardiovascular Disease Risk Factors According to Body Mass Index in US Adults JAMA, April 20, 2005; 293(15): 1868 - 1874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. O. Bonow, A. O. Grant, and A. K. Jacobs The Cardiovascular State of the Union: Confronting Healthcare Disparities Circulation, March 15, 2005; 111(10): 1205 - 1207. [Full Text] [PDF]
|
|
|
|
|
|
D. A. Rhoades Racial Misclassification and Disparities in Cardiovascular Disease Among American Indians and Alaska Natives Circulation, March 15, 2005; 111(10): 1250 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Mensah Eliminating Disparities in Cardiovascular Health: Six Strategic Imperatives and a Framework for Action Circulation, March 15, 2005; 111(10): 1332 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Sonnenschein and J. A. Brody Effect of Population Aging on Proportionate Mortality From Heart Disease and Cancer, U.S. 2000-2050 J. Gerontol. B. Psychol. Sci. Soc. Sci., March 1, 2005; 60(2): S110 - S112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Williams and P. B. Jackson Social Sources Of Racial Disparities In Health Health Aff., March 1, 2005; 24(2): 325 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Latowsky Complexity of risk determination Can. Med. Assoc. J., February 1, 2005; 172(3): 309 - 309. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pajunen, R. Paakkonen, H. Hamalainen, I. Keskimaki, T. Laatikainen, M. Niemi, H. Rintanen, and V. Salomaa Trends in Fatal and Nonfatal Strokes Among Persons Aged 35 to >=85 Years During 1991-2002 in Finland Stroke, February 1, 2005; 36(2): 244 - 248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Avendano, A. E. Kunst, F. van Lenthe, V. Bos, G. Costa, T. Valkonen, M. Cardano, S. Harding, J-K. Borgan, M. Glickman, et al. Trends in Socioeconomic Disparities in Stroke Mortality in Six European Countries between 1981-1985 and 1991-1995 Am. J. Epidemiol., January 1, 2005; 161(1): 52 - 61. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Daviglus, K. Liu, L. L. Yan, A. Pirzada, L. Manheim, W. Manning, D. B. Garside, R. Wang, A. R. Dyer, P. Greenland, et al. Relation of Body Mass Index in Young Adulthood and Middle Age to Medicare Expenditures in Older Age JAMA, December 8, 2004; 292(22): 2743 - 2749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. D. Woodard, N. R. Kressin, and L. A. Petersen Is Lipid-Lowering Therapy Underused by African Americans at High Risk of Coronary Heart Disease Within the VA Health Care System? Am J Public Health, December 1, 2004; 94(12): 2112 - 2117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Koren, D. B. Hunninghake, and the ALLIANCE Investigators Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: The alliance study J. Am. Coll. Cardiol., November 2, 2004; 44(9): 1772 - 1779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Pradhan, A. Z. LaCroix, R. D. Langer, M. Trevisan, C. E. Lewis, J. A. Hsia, A. Oberman, J. M. Kotchen, and P. M Ridker Tissue Plasminogen Activator Antigen and D-Dimer as Markers for Atherothrombotic Risk Among Healthy Postmenopausal Women Circulation, July 20, 2004; 110(3): 292 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. H. Ambriz, L. D. Woodard, N. R. Kressin, and L. A. Petersen Use of Smoking Cessation Interventions and Aspirin for Secondary Prevention: Are There Racial Disparities? American Journal of Medical Quality, July 1, 2004; 19(4): 166 - 171. [Abstract] [PDF]
|
|
|
|
 |
|
 E. W. Gregg, P. Sorlie, R. Paulose-Ram, Q. Gu, M. S. Eberhardt, M. Wolz, V. Burt, L. Curtin, M. Engelgau, and L. Geiss Prevalence of Lower-Extremity Disease in the U.S. Adult Population >=40 Years of Age With and Without Diabetes: 1999-2000 National Health and Nutrition Examination Survey Diabetes Care, July 1, 2004; 27(7): 1591 - 1597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Cossrow and B. Falkner Race/Ethnic Issues in Obesity and Obesity-Related Comorbidities J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2590 - 2594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. F. Gordon, M. Gulanick, F. Costa, G. Fletcher, B. A. Franklin, E. J. Roth, and T. Shephard Physical Activity and Exercise Recommendations for Stroke Survivors: An American Heart Association Scientific Statement From the Council on Clinical Cardiology, Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention; the Council on Cardiovascular Nursing; the Council on Nutrition, Physical Activity, and Metabolism; and the Stroke Council Stroke, May 1, 2004; 35(5): 1230 - 1240. [Full Text] [PDF]
|
|
|
|
|
|
N. F. Gordon, M. Gulanick, F. Costa, G. Fletcher, B. A. Franklin, E. J. Roth, and T. Shephard Physical Activity and Exercise Recommendations for Stroke Survivors: An American Heart Association Scientific Statement From the Council on Clinical Cardiology, Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention; the Council on Cardiovascular Nursing; the Council on Nutrition, Physical Activity, and Metabolism; and the Stroke Council Circulation, April 27, 2004; 109(16): 2031 - 2041. [Full Text] [PDF]
|
|
|
|
|
|
K. Sundquist, M. Winkleby, H. Ahlen, and S.-E. Johansson Neighborhood Socioeconomic Environment and Incidence of Coronary Heart Disease: A Follow-up Study of 25,319 Women and Men in Sweden Am. J. Epidemiol., April 1, 2004; 159(7): 655 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Disparities in Premature Deaths From Heart Disease--50 States and the District of Columbia, 2001 JAMA, March 17, 2004; 291(11): 1316 - 1317. [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Dunn, R. A. Ariens, M. de Lange, H. Snieder, J. H. Turney, T. D. Spector, and P. J. Grant Genetics of fibrin clot structure: a twin study Blood, March 1, 2004; 103(5): 1735 - 1740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. O. Bonow and S. C. Smith Jr Cardiovascular Manpower: The Looming Crisis Circulation, February 24, 2004; 109(7): 817 - 820. [Full Text] [PDF]
|
|
|
|
|
|
K. J. Greenlund, Z. J. Zheng, N. L. Keenan, W. H. Giles, M. L. Casper, G. A. Mensah, and J. B. Croft Trends in Self-reported Multiple Cardiovascular Disease Risk Factors Among Adults in the United States, 1991-1999 Arch Intern Med, January 26, 2004; 164(2): 181 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. H. Messerli, E. Grossman, and A. F. Lever Do Thiazide Diuretics Confer Specific Protection Against Strokes? Arch Intern Med, November 24, 2003; 163(21): 2557 - 2560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Daviglus, K. Liu, L. L. Yan, A. Pirzada, D. B. Garside, L. Schiffer, A. R. Dyer, P. Greenland, and J. Stamler Body Mass Index in Middle Age and Health-Related Quality of Life in Older Age: The Chicago Heart Association Detection Project in Industry Study Arch Intern Med, November 10, 2003; 163(20): 2448 - 2455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Daviglus, K. Liu, A. Pirzada, L. L. Yan, D. B. Garside, J. Feinglass, J. M. Guralnik, P. Greenland, and J. Stamler Favorable Cardiovascular Risk Profile in Middle Age and Health-Related Quality of Life in Older Age Arch Intern Med, November 10, 2003; 163(20): 2460 - 2468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Cutler and T. Thom Trends in Stroke Mortality Circulation, October 14, 2003; 108 (15): e108 - e108. [Full Text] [PDF]
|
|
|
|
|
|
J. S. Elkins and S. C. Johnston Thirty-Year Projections for Deaths From Ischemic Stroke in the United States Stroke, September 1, 2003; 34(9): 2109 - 2112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Galobardes, M. C. Costanza, M. S. Bernstein, C. Delhumeau, and A. Morabia Trends in Risk Factors for Lifestyle-Related Diseases by Socioeconomic Position in Geneva, Switzerland, 1993-2000: Health Inequalities Persist Am J Public Health, August 1, 2003; 93(8): 1302 - 1309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. G. Nabel Cardiovascular Disease N. Engl. J. Med., July 3, 2003; 349(1): 60 - 72. [Full Text] [PDF]
|
|
|
|
|
|
T. S. M. Tsang, G. W. Petty, M. E. Barnes, W. M. O'Fallon, K. R. Bailey, D. O. Wiebers, J. D. Sicks, T. J. H. Christianson, J. B. Seward, and B. J. Gersh The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: Changes over three decades J. Am. Coll. Cardiol., July 2, 2003; 42(1): 93 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Peeters, L. Bonneux, J. J. Barendregt, and J. P. Mackenbach Improvements in Treatment of Coronary Heart Disease and Cessation of Stroke Mortality Rate Decline Stroke, July 1, 2003; 34(7): 1610 - 1614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Pasternak, J. Abrams, P. Greenland, L. A. Smaha, P. W. F. Wilson, and N. Houston-Miller Task force #1--identification of coronary heart disease risk: is there a detection gap? J. Am. Coll. Cardiol., June 4, 2003; 41(11): 1863 - 1874. [Full Text] [PDF]
|
|
|
|
|
|
T. Truelsen, M. Mahonen, H. Tolonen, K. Asplund, R. Bonita, and D. Vanuzzo Trends in Stroke and Coronary Heart Disease in the WHO MONICA Project Stroke, June 1, 2003; 34(6): 1346 - 1352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Wolf-Maier, R. S. Cooper, J. R. Banegas, S. Giampaoli, H.-W. Hense, M. Joffres, M. Kastarinen, N. Poulter, P. Primatesta, F. Rodriguez-Artalejo, et al. Hypertension Prevalence and Blood Pressure Levels in 6 European Countries, Canada, and the United States JAMA, May 14, 2003; 289(18): 2363 - 2369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J A Critchley and B Unal Health effects associated with smokeless tobacco: a systematic review Thorax, May 1, 2003; 58(5): 435 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J A Critchley and S Capewell Substantial potential for reductions in coronary heart disease mortality in the UK through changes in risk factor levels J Epidemiol Community Health, April 1, 2003; 57(4): 243 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Cooper and B. M. Psaty Genomics and Medicine: Distraction, Incremental Progress, or the Dawn of a New Age? Ann Intern Med, April 1, 2003; 138(7): 576 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. N.H. Enzweiler, T. H. Wiese, J. Petersein, A. E. Lembcke, A. C. Borges, P. Dohmen, U. Hoffmann, and B. Hamm Diameter changes of occluded venous coronary artery bypass grafts in electron beam tomography: preliminary findings Eur. J. Cardiothorac. Surg., March 1, 2003; 23(3): 347 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Pearson, T. L. Bazzarre, S. R. Daniels, J. M. Fair, S. P. Fortmann, B. A. Franklin, L. B. Goldstein, Y. Hong, G. A. Mensah, J. F. Sallis Jr, et al. American Heart Association Guide for Improving Cardiovascular Health at the Community Level: A Statement for Public Health Practitioners, Healthcare Providers, and Health Policy Makers From the American Heart Association Expert Panel on Population and Prevention Science Circulation, February 4, 2003; 107(4): 645 - 651. [Full Text] [PDF]
|
|
|
|
|
|
R. O. Bonow The Challenge of Balancing Scientific Discovery and Translation Circulation, January 28, 2003; 107(3): 358 - 362. [Full Text] [PDF]
|
|
|
|
|
|
A. P. Miller and S. Oparil Secondary Prevention of Coronary Heart Disease in Women: A Call to Action Ann Intern Med, January 21, 2003; 138(2): 150 - 151. [Full Text] [PDF]
|
|
|
|
|
|
L. A. Cobb, C. E. Fahrenbruch, M. Olsufka, and M. K. Copass Changing Incidence of Out-of-Hospital Ventricular Fibrillation, 1980-2000 JAMA, December 18, 2002; 288(23): 3008 - 3013. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Rubins, S. J. Robins, D. Collins, D. B. Nelson, M. B. Elam, E. J. Schaefer, F. H. Faas, J. W. Anderson, and for the VA-HIT Study Group Diabetes, Plasma Insulin, and Cardiovascular Disease: Subgroup Analysis From the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) Arch Intern Med, December 9, 2002; 162(22): 2597 - 2604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y Khaykin, P C Austin, J V Tu, and D A Alter Utilisation of coronary angiography after acute myocardial infarction in Ontario over time: have referral patterns changed? Heart, December 1, 2002; 88(5): 460 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. O. Bonow, L. A. Smaha, S. C. Smith Jr, G. A. Mensah, and C. Lenfant World Heart Day 2002: The International Burden of Cardiovascular Disease: Responding to the Emerging Global Epidemic Circulation, September 24, 2002; 106(13): 1602 - 1605. [Full Text] [PDF]
|
|
|
|
 |
|
 K. O. Akosah, A. M. Schaper, P. Havlik, S. Barnhart, and S. Devine Improving Care for Patients With Chronic Heart Failure in the Community* : The Importance of a Disease Management Program Chest, September 1, 2002; 122(3): 906 - 912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Benjamin, S. C. Smith Jr, R. S. Cooper, M. N. Hill, and R. V. Luepker Task Force #1--magnitude of the prevention problem: opportunities and challenges J. Am. Coll. Cardiol., August 21, 2002; 40(4): 588 - 603. [Full Text] [PDF]
|
|
|
|
|
|
C. N. B. Merz, G. A. Mensah, V. Fuster, P. Greenland, and P. D. Thompson Task Force #5--the role of cardiovascular specialists as leaders in prevention: from training to champion J. Am. Coll. Cardiol., August 21, 2002; 40(4): 641 - 649. [Full Text] [PDF]
|
|
|
|
|
|
M. J. LaMonte, J. L. Durstine, F. G. Yanowitz, T. Lim, K. D. DuBose, P. Davis, and B. E. Ainsworth Cardiorespiratory Fitness and C-Reactive Protein Among a Tri-Ethnic Sample of Women Circulation, July 23, 2002; 106(4): 403 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. de Gaudemaris, T. Lang, G. Chatellier, L. Larabi, V. Lauwers-Cances, A. Maitre, and E. Diene Socioeconomic Inequalities in Hypertension Prevalence and Care: The IHPAF Study Hypertension, June 1, 2002; 39(6): 1119 - 1125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. de Lorgeril, P. Salen, F. Paillard, F. Laporte, F. Boucher, and J. de Leiris Mediterranean diet and the French paradox: Two distinct biogeographic concepts for one consolidated scientific theory on the role of nutrition in coronary heart disease Cardiovasc Res, June 1, 2002; 54(3): 503 - 515. [Full Text] [PDF]
|
|
|
|
|
|
W. A. Wattigney, G. A. Mensah, and J. B. Croft Increased Atrial Fibrillation Mortality: United States, 1980-1998 Am. J. Epidemiol., May 1, 2002; 155(9): 819 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Cornelius, P. L. Smith, and G. M. Simpson What Factors Hinder Women of Color From Obtaining Preventive Health Care? Am J Public Health, April 1, 2002; 92(4): 535 - 539. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. A. Manolio and D. E. Bild Coronary Calcium, Race, and Genes Arterioscler. Thromb. Vasc. Biol., March 1, 2002; 22(3): 359 - 360. [Full Text] [PDF]
|
|
|
|
|
|
B. L. Rodriguez, R. D'Agostino, R. D. Abbott, A. Kagan, C. M. Burchfiel, K. Yano, G. W. Ross, H. Silbershatz, M. W. Higgins, J. Popper, et al. Risk of Hospitalized Stroke in Men Enrolled in the Honolulu Heart Program and the Framingham Study: A Comparison of Incidence and Risk Factor Effects * Editorial Comment: A Comparison of Incidence and Risk Factor Effects Stroke, January 1, 2002; 33(1): 230 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Daviglus and J. Stamler Major risk factors and coronary heart disease: much has been achieved but crucial challenges remain J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1018 - 1022. [Full Text] [PDF]
|
|
|
|
|
|
G. Howard, V. J. Howard, C. Katholi, M. K. Oli, S. Huston, and K. Asplund Decline in US Stroke Mortality: An Analysis of Temporal Patterns by Sex, Race, and Geographic Region Editorial Comment: An Analysis of Temporal Patterns by Sex, Race, and Geographic Region Stroke, October 1, 2001; 32(10): 2213 - 2220. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||